SAVE RARE TREATMENTS TASK FORCE

Lobbying client · District of Columbia · filed 2025 to 2026

Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.

$300,000 Reported spend

6 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (58112), not by name.

Firms hired 1

LEAVITT PARTNERS, LLC $300,000 6 filings

Reported by year 2 years

2026 $90,000 2 filings
2025 $210,000 4 filings

Issues lobbied 1

Health Issues 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 6 total

Q2

LEAVITT PARTNERS, LLC

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $40,000 income · posted Jul 15, 2026

View → Q1

LEAVITT PARTNERS, LLC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $50,000 income · posted Apr 20, 2026

View → Q4

LEAVITT PARTNERS, LLC

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $40,000 income · posted Jan 9, 2026

View → Q3

LEAVITT PARTNERS, LLC

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $50,000 income · posted Oct 20, 2025

View → Q2

LEAVITT PARTNERS, LLC

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $80,000 income · posted Jul 15, 2025

View → Q1

LEAVITT PARTNERS, LLC

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $40,000 income · posted Apr 22, 2025

View →

Affiliated organisations 2

AGIOS PHARMACEUTICALS United States of America named on 1 filing
ALKERMES, INC. United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.